Phaseline

Targets › CLN3

CLN3 (Battenin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Sep 2029.

Mediates microtubule-dependent, anterograde transport connecting the Golgi network, endosomes, autophagosomes, lysosomes and plasma membrane, and participates in several cellular processes such as regulation of lysosomal pH, lysosome protein degradation, receptor-mediated endocytosis, autophagy, transport of proteins and lipids from the TGN, apoptosis and synaptic transmission. Facilitates the proteins transport…. (UniProt, Q13286)

Open in Phaseline: the race on CLN3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Neela TherapeuticsCLN-301
Intrathecal AAV9 gene therapy for CLN3 replacement
CLN3Phase 1CLN3Sep 2029

Conditions

CLN3 (1)

Modalities

other (1)

Companies

Neela Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.